Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,108
archived clinical trials in
Lupus

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus
A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus
Status: Archived
Clinical Research Facility
mi
from
Houston, TX
PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus
A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Houston, TX
Velcade for Proliferative Lupus Nephritis
Velcade for Proliferative Lupus Nephritis
Status: Archived
The Rogosin Institute
mi
from
, NY
Velcade for Proliferative Lupus Nephritis
Velcade for Proliferative Lupus Nephritis
Status: Archived
Updated: 1/1/1970
The Rogosin Institute
mi
from
, NY
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus: Phase II Trial
Status: Enrolling
Updated:  12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus: Phase II Trial
Status: Enrolling
Updated: 12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus: Phase II Trial
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus: Phase II Trial
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Sirolimus for Autoimmune Disease of Blood Cells
Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Sirolimus for Autoimmune Disease of Blood Cells
Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Duke Autoimmunity in Pregnancy Registry
Duke Autoimmunity in Pregnancy Registry
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Duke Autoimmunity in Pregnancy Registry
Duke Autoimmunity in Pregnancy Registry
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Sbi-087 Administered To Subjects With Systemic Lupus Erythematosus.
Status: Enrolling
Updated:  12/31/1969
Arthritis & Rheumatology Care Center
mi
from
South Miami, FL
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Sbi-087 Administered To Subjects With Systemic Lupus Erythematosus.
Status: Enrolling
Updated: 12/31/1969
Arthritis & Rheumatology Care Center
mi
from
South Miami, FL
Click here to add this to my saved trials
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Sbi-087 Administered To Subjects With Systemic Lupus Erythematosus.
Status: Enrolling
Updated:  12/31/1969
Miami Research Associates
mi
from
South Miami, FL
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Sbi-087 Administered To Subjects With Systemic Lupus Erythematosus.
Status: Enrolling
Updated: 12/31/1969
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Sbi-087 Administered To Subjects With Systemic Lupus Erythematosus.
Status: Enrolling
Updated:  12/31/1969
MRA Clinical Research, LLC
mi
from
South Miami, FL
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Sbi-087 Administered To Subjects With Systemic Lupus Erythematosus.
Status: Enrolling
Updated: 12/31/1969
MRA Clinical Research, LLC
mi
from
South Miami, FL
Click here to add this to my saved trials
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Sbi-087 Administered To Subjects With Systemic Lupus Erythematosus.
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Sbi-087 Administered To Subjects With Systemic Lupus Erythematosus.
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Sbi-087 Administered To Subjects With Systemic Lupus Erythematosus.
Status: Enrolling
Updated:  12/31/1969
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Sbi-087 Administered To Subjects With Systemic Lupus Erythematosus.
Status: Enrolling
Updated: 12/31/1969
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Sbi-087 Administered To Subjects With Systemic Lupus Erythematosus.
Status: Enrolling
Updated:  12/31/1969
Metroplex Clinical Research Center
mi
from
Dallas, TX
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Sbi-087 Administered To Subjects With Systemic Lupus Erythematosus.
Status: Enrolling
Updated: 12/31/1969
Metroplex Clinical Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Miami, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Glendale, AZ
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mesa, AZ
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Paradise Valley, AZ
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Paradise Valley, AZ
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Peoria, AZ
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Peoria, AZ
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Anaheim, CA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Glendale, CA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lakewood, CA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lakewood, CA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Long Beach, CA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Leandro, CA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Leandro, CA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Upland, CA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Upland, CA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Danbury, CT
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Danbury, CT
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Farmington, CT
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Farmington, CT
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Norwich, CT
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Norwich, CT
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Trumbull, CT
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Trumbull, CT
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boca Raton, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Clearwater, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Clearwater, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Doral, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Doral, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lake Mary, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lake Mary, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Orange Park, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orange Park, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Palm Harbor, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tamarac, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tamarac, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Decatur, GA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Marietta, GA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boise, ID
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boise, ID
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Peoria, IL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Peoria, IL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Muncie, IN
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Muncie, IN
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Kansas City, KA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials